Wound healing agent and preparation method thereof

Abstract

The invention relates to the technical field of wound healing, and provides a wound healing agent and a preparation method thereof.The wound healing agent is prepared from, by mass, 0.5-2 parts of chitosan, 0.01-0.1 part of hypochlorous acid, 0.02-0.05 part of colloidal silver particles, 0.01-0.05 part of plant extract, 1-2 parts of auxiliary components and 90-100 parts of medical purified water; wherein the plant extract comprises tea polyphenol and an aloe extract; the auxiliary components comprise a solubilizer, a stabilizer, a humectant and an antioxidant. According to the wound healing agent, a sterile environment can be rapidly and effectively formed on a wound and around the wound, and then through the high potential of the agent, nerve cells are activated, the immunity and the self-repairing capacity of a human body are improved, and the effect of rapidly healing the wound is achieved.

Description

Technical Field

[0001] The present invention relates to the technical field of wound healing, and in particular to a wound healing agent and a preparation method thereof. Background Art

[0002] Wound infection refers to the pathological reaction of pathogenic microorganisms invading the body through the wound, growing and multiplying in the body, causing damage to the body's normal functions, metabolism, and tissue structure, and causing tissue damage. If the wound is infected and symptoms such as local redness, swelling, heat and pain, or pus clots appear, if it is not treated or controlled in time, the ulcerated wound will become larger and larger; Staphylococcus aureus may also appear in the infected area, which may lead to impetigo and cellulitis, and in severe cases may even cause nausea, vomiting, fever, and even mental confusion and other systemic discomfort symptoms.

[0003] However, the blood sugar level of diabetics is high, and high blood sugar can cause hemoglobin glycosylation, accompanied by narrowing of blood vessels and changes in red blood cell membranes, leading to insufficient oxygen supply to wound tissues and causing vascular lesions. Vascular lesions reduce or even lose basic "feelings" and "pain," causing the nervous system to become insensitive to wounds. On this basis, bacterial infection and biofilm formation further deteriorate the wound microenvironment. In short, oxidative stress caused by high blood sugar promotes the expression of pro-inflammatory factors in tissues, causing diabetic neuropathy and vascular lesions. Further bacterial infection worsens the wounds of diabetic patients, causing the wounds to not heal for a long time.

[0004] In view of this, a wound healing agent and a preparation method thereof are urgently needed. Summary of the invention

[0005] The purpose of the present invention is to provide a wound healing agent and a preparation method thereof in view of the deficiencies in the prior art.

[0006] To achieve the above object, the technical solution adopted by the present invention is:

[0007] The first aspect of the present invention is to provide a wound healing agent, which comprises, by weight:

[0008] Chitosan: 0.5-2 parts,

[0009] Hypochlorous acid: 0.01-0.1 parts,

[0010] Colloidal silver particles: 0.02-0.05 parts,

[0011] Plant extract: 0.01-0.05 parts,

[0012] Auxiliary ingredients: 1-2 parts,

[0013] Medical purified water: 90 parts to 100 parts;

[0014] The plant extracts include tea polyphenols and aloe extracts; the auxiliary ingredients include solubilizers, stabilizers, moisturizers, and antioxidants.

[0015] Preferably, the particle size of the colloidal silver particles is 10nm-50nm; or / and the chitosan is medical chitosan.

[0016] Preferably, in the plant extract, the mass ratio of tea polyphenols to aloe extract is 1:(1-1.2); or / and in the auxiliary ingredients, the mass ratio of solubilizer, stabilizer, moisturizer, and antioxidant is 1:(0.02-0.5):(0.01-0.2):(0.01-0.1).

[0017] Preferably, the pH of the wound healing agent is less than 2.7; or / and the redox potential value of the wound healing agent is greater than 1100 MV.

[0018] The second aspect of the present invention is a method for preparing a wound healing agent, comprising:

[0019] S100, preparing a chitosan solution: adding chitosan and a solubilizing agent into medical purified water, and stirring until the chitosan is completely dissolved to obtain a chitosan solution;

[0020] S200, preparing a hypochlorous acid solution: preparing a sodium chloride solution, and electrolyzing the sodium chloride solution to obtain a hypochlorous acid solution;

[0021] S300, preparing a wound healing agent: slowly adding a hypochlorous acid solution to a chitosan solution, adding a stabilizer to adjust the pH, stirring evenly, and adding colloidal silver particles, a plant extract, a moisturizer, and an antioxidant during stirring to obtain a wound healing agent;

[0022] The concentration of the chitosan solution is 5g / L-20g / L; the concentration of the sodium chloride solution is 10g / L-20g / L; and the plant extracts include tea polyphenols and aloe extracts.

[0023] Preferably, the method for preparing colloidal silver particles comprises:

[0024] S301, dissolving silver nitrate in medical purified water and stirring, and slowly dropping a reducing agent solution and a silver ion stabilizer during the stirring process until the solution turns light yellow or brown;

[0025] S302, cooling the solution in S301 and centrifuging it to obtain colloidal silver particles;

[0026] Among them, the concentration of the silver nitrate solution is 0.01mol / L-0.1mol / L; the concentration of the reducing agent solution is 0.1mol / L-0.2mol / L.

[0027] Preferably, in S301, the stirring treatment is carried out in a shaded or dark place; or / and the stirring treatment temperature is 60°C-80°C; or / and the stirring treatment time is 10min-30min; or / and the reducing agent solution is sodium citrate solution or ascorbic acid solution; or / and the silver ion stabilizer is sodium citrate or polyvinyl pyrrolidone.

[0028] Preferably, in S300, the pH is adjusted to less than 2.7; or / and S300 is performed under ultrasonic conditions.

[0029] Preferably, in S200, the voltage of the electrolysis treatment is 4V-6V; or / and the time of the electrolysis treatment is 10min-30min; or / and the temperature of the electrolysis treatment is 20°C-30°C.

[0030] Preferably, the solubilizer includes: any one of acetic acid, lactic acid, carboxymethyl cellulose, phospholipids, and polysorbate; or / and the stabilizer includes: any one of citric acid, sodium citrate, lactic acid, and sodium lactate; or / and the humectant includes: any one of glycerol, hyaluronic acid, propylene glycol, polyvinyl alcohol, and ceramide; or / and the antioxidant includes: any one of vitamin E, glutathione, ascorbic acid, BHT, rosemary extract, and β-carotene extract.

[0031] The present invention adopts the above technical solution, and has the following technical effects compared with the prior art:

[0032] The wound healing agent of the present invention and the wound healing agent in the preparation method thereof can quickly and effectively form a sterile environment in and around the wound, and then activate nerve cells through the high potential of the agent itself, thereby improving the body's immunity and self-repair ability, thereby achieving the effect of rapid wound healing; the wound healing agent can form a protective film on the wound surface, inhibit bacterial growth, improve cell vitality, help cell repair, and effectively control wound infection caused by diabetes, keep the wound surface clean for a long time, and promote granulation. DETAILED DESCRIPTION

[0033] The specific embodiments of the present invention will be described in detail below.

[0034] Unless otherwise defined, technical or scientific terms used in the claims and the specification shall have the common meanings understood by persons having ordinary skills in the technical field to which the present invention belongs.

[0035] The words "include" or similar words used in the patent application specification and claims of the present invention mean that the items appearing before "include" include the items listed after "include" or their equivalents, and do not exclude other items.

[0036] The numerical values ​​mentioned in the present invention include all numerical values ​​that increase from low to high by one unit, assuming that there are at least two units between any lower value and the higher value. For example, if a component or a physical quantity is said to be from 1 to 100, 10 to 90 is more preferred, and 20 to 80 is the most preferred, it is intended to express that values ​​such as 5 to 95, 14 to 76, 23 to 67, 32 to 58, 41 to 49 are clearly listed in this specification; for values ​​less than 1, 0.0001, 0.001, 0.01 or 0.1 are considered to be more suitable as a unit. The above examples are for illustrative purposes only. In fact, all numerical combinations between the lowest value and the highest value listed are deemed to be clearly listed in this specification in a similar manner.

[0037] Example 1

[0038] This embodiment provides a wound healing agent, which comprises, by weight:

[0039] Chitosan: 0.5 parts,

[0040] Hypochlorous acid: 0.01 parts,

[0041] Colloidal silver particles: 0.02 parts,

[0042] Plant extract: 0.01 parts,

[0043] Auxiliary ingredients: 1 part,

[0044] Medical purified water: 90 parts;

[0045] The plant extracts include tea polyphenols and aloe extracts, and the mass ratio of tea polyphenols to aloe extracts is 1:1; the auxiliary components include solubilizers, stabilizers, moisturizers, and antioxidants, and the mass ratio of solubilizers, stabilizers, moisturizers, and antioxidants is 1:0.02:0.01:0.01; the particle size of the colloidal silver particles is 10nm;

[0046] The preparation method of the wound healing agent comprises:

[0047] S100, preparing a chitosan solution: adding chitosan and acetic acid to medical purified water, stirring until the chitosan is completely dissolved, to obtain a chitosan solution;

[0048] S200, preparing a hypochlorous acid solution: preparing a sodium chloride solution, and electrolyzing the sodium chloride solution at a voltage of 4 V, a time of 30 min, and a temperature of 30° C. to obtain a hypochlorous acid solution;

[0049] S300, preparing a wound healing agent: slowly adding a hypochlorous acid solution to a chitosan solution, adding citric acid to adjust the pH to less than 2.7, stirring evenly, and adding colloidal silver particles, tea polyphenols and aloe extract, glycerin, and vitamin E during stirring to obtain a wound healing agent;

[0050] Wherein, the concentration of chitosan solution is 5 g / L; the concentration of sodium chloride solution is 10 g / L; and the colloidal silver particles are purchased from outside.

[0051] Example 2

[0052] This embodiment provides a wound healing agent, which comprises, by weight:

[0053] Chitosan: 2 parts,

[0054] Hypochlorous acid: 0.1 parts,

[0055] Colloidal silver particles: 0.05 parts,

[0056] Plant extract: 0.05 parts,

[0057] Auxiliary ingredients: 2 parts,

[0058] Medical purified water: 100 parts;

[0059] The plant extracts include tea polyphenols and aloe extracts, and the mass ratio of tea polyphenols to aloe extracts is 1:1.2; the auxiliary components include solubilizers, stabilizers, moisturizers, and antioxidants, and the mass ratio of solubilizers, stabilizers, moisturizers, and antioxidants is 1:0.5:0.2:0.1; the particle size of the colloidal silver particles is 50nm;

[0060] The preparation method of the wound healing agent comprises:

[0061] S100, preparing a chitosan solution: adding chitosan and carboxymethyl cellulose into medical purified water, stirring until the chitosan is completely dissolved, to obtain a chitosan solution;

[0062] S200, preparing a hypochlorous acid solution: preparing a sodium chloride solution, and electrolyzing the sodium chloride solution at a voltage of 6 V, a time of 10 min, and a temperature of 20° C. to obtain a hypochlorous acid solution;

[0063] S300, preparing a wound healing agent: slowly adding a hypochlorous acid solution to a chitosan solution, adding lactic acid to adjust the pH to less than 2.7, stirring evenly, and adding colloidal silver particles, tea polyphenols and aloe extract, hyaluronic acid, and ascorbic acid during stirring to obtain a wound healing agent;

[0064] Wherein, the concentration of chitosan solution is 20g / L; the concentration of sodium chloride solution is 20g / L; the colloidal silver particles are purchased from outside.

[0065] Example 3

[0066] This embodiment provides a wound healing agent, which comprises, by weight:

[0067] Chitosan: 1 part,

[0068] Hypochlorous acid: 0.08 parts,

[0069] Colloidal silver particles: 0.03 parts,

[0070] Plant extract: 0.03 parts,

[0071] Auxiliary ingredients: 1 part,

[0072] Medical purified water: 95 parts;

[0073] The plant extracts include tea polyphenols and aloe extracts, and the mass ratio of tea polyphenols to aloe extracts is 1:1.1; the auxiliary components include solubilizers, stabilizers, moisturizers, and antioxidants, and the mass ratio of solubilizers, stabilizers, moisturizers, and antioxidants is 1:0.3:0.1:0.1; the particle size of the colloidal silver particles is 30nm;

[0074] The preparation method of the wound healing agent comprises:

[0075] S100, preparing a chitosan solution: adding chitosan and lactic acid into medical purified water, stirring until the chitosan is completely dissolved, to obtain a chitosan solution;

[0076] S200, preparing a hypochlorous acid solution: preparing a sodium chloride solution, and electrolyzing the sodium chloride solution at a voltage of 5 V, a time of 20 min, and a temperature of 25° C. to obtain a hypochlorous acid solution;

[0077] S300, preparing a wound healing agent: slowly adding a hypochlorous acid solution to a chitosan solution, adding sodium citrate to adjust the pH to less than 2.7, stirring evenly, and adding colloidal silver particles, tea polyphenols and aloe extract, propylene glycol, and β-carotene extract during stirring to obtain a wound healing agent;

[0078] Wherein, the concentration of the chitosan solution is 15 g / L; the concentration of the sodium chloride solution is 10 g / L; the preparation method of the colloidal silver particles comprises:

[0079] S301, dissolving 0.01 mol / L silver nitrate in medical purified water and stirring at 60° C. for 10 min, slowly adding 0.1 mol / L ascorbic acid solution and polyvinyl pyrrolidone dropwise during the stirring process until the solution turns light yellow or brown;

[0080] S302, cooling the solution in S301 and centrifuging it to obtain colloidal silver particles.

[0081] Example 4

[0082] This embodiment provides a wound healing agent, which comprises, by weight:

[0083] Chitosan: 1 part,

[0084] Hypochlorous acid: 0.07 parts,

[0085] Colloidal silver particles: 0.02 parts,

[0086] Plant extract: 0.04 parts,

[0087] Auxiliary ingredients: 2 parts,

[0088] Medical purified water: 94 parts;

[0089] The plant extracts include tea polyphenols and aloe extracts, and the mass ratio of tea polyphenols to aloe extracts is 1:1; the auxiliary components include solubilizers, stabilizers, moisturizers, and antioxidants, and the mass ratio of the solubilizers, stabilizers, moisturizers, and antioxidants is 1:0.2:0.1:0.1; the particle size of the colloidal silver particles is 30nm;

[0090] The preparation method of the wound healing agent comprises:

[0091] S100, preparing a chitosan solution: adding chitosan and phospholipids into medical purified water, stirring until the chitosan is completely dissolved, to obtain a chitosan solution;

[0092] S200, preparing a hypochlorous acid solution: preparing a sodium chloride solution, and electrolyzing the sodium chloride solution at a voltage of 5 V, a time of 20 min, and a temperature of 25° C. to obtain a hypochlorous acid solution;

[0093] S300, preparing a wound healing agent: slowly adding a hypochlorous acid solution to a chitosan solution, adding sodium lactate to adjust the pH to less than 2.7, stirring evenly, and adding colloidal silver particles, tea polyphenols and aloe extract, ceramide, and glutathione during stirring to obtain a wound healing agent;

[0094] Wherein, the concentration of chitosan solution is 12g / L; the concentration of sodium chloride solution is 15g / L; the preparation method of colloidal silver particles comprises:

[0095] S301, dissolving 0.1 mol / L silver nitrate in medical purified water and stirring at 80° C. for 30 min, slowly adding 0.2 mol / L sodium citrate solution and sodium citrate dropwise during the stirring process until the solution turns light yellow or brown;

[0096] S302, cooling the solution in S301 and centrifuging it to obtain colloidal silver particles.

[0097] Comparative Example

[0098] This comparative example provides a wound healing agent, which is purchased from outside and mainly consists of chitosan, lactic acid and medical purified water.

[0099] Performance Testing

[0100] The wound healing agents in Examples 1-4 and Comparative Example 1 were sampled and tested. The test results are shown in Table 1.

[0101] Antibacterial test: Staphylococcus aureus was inoculated on the wound healing agents in Examples 1-4 and Comparative Example 1, and the diameter of the antibacterial zone was detected after culturing for 48 hours;

[0102] Cytotoxicity test: The wound healing agents in Examples 1-4 and Comparative Example 1 were diluted and treated with human skin keratinocytes, and cultured for 48 hours, and the cell activity was detected using MTT reagent;

[0103] Wound healing ability test: Standardized wounds were prepared on mice, and the wound healing agents in Examples 1-4 and Comparative Example 1 were used to treat them, respectively. The wound healing area was measured after one week.

[0104] Table 1

[0105]

[0106]

[0107] It can be seen from Table 1 that the various properties of the wound healing agents in Examples 1-4 are better than those in the comparative example, indicating that the wound healing agents in the embodiments of the present invention can promote wound healing faster and better than those in the comparative example. The sunscreen knitted fabrics in Examples 3-4 have better wound healing performance than those in Examples 1-2, which may be due to the fact that Examples 3-4 adopt the preparation method of the colloidal silver particles provided in the present invention and more suitable parameters, so they have better performance.

[0108] In summary, the wound healing agent of the present invention and its preparation method can quickly and effectively form a sterile environment in and around the wound, and then activate nerve cells through the high potential of the agent itself, thereby improving the body's immunity and self-repair ability, thereby achieving the effect of rapid wound healing; the wound healing agent can form a protective film on the wound surface, inhibit bacterial growth, improve cell vitality, help cell repair, and effectively control wound infection caused by diabetes, keep the wound surface clean for a long time, and promote granulation.

[0109] The above are only preferred embodiments of the present invention, and are not intended to limit the implementation methods and protection scope of the present invention. Those skilled in the art should be aware that all solutions obtained by equivalent substitutions and obvious changes made using the description and content of the present invention should be included in the protection scope of the present invention.

Claims

1. A wound healing agent, characterized in that: Calculated by mass, including: Chitosan: 0.5-2 parts, Hypochlorous acid: 0.01-0.1 parts, Colloidal silver particles: 0.02-0.05 parts, Plant extract: 0.01-0.05 parts Auxiliary ingredients: 1-2 parts, Medical purified water: 90 parts to 100 parts; Wherein, the plant extracts include: tea polyphenols and aloe extracts; The auxiliary ingredients include: solubilizers, stabilizers, humectants, and antioxidants.

2. The wound healing agent according to claim 1, characterized in that The colloidal silver particles have a particle size of 10nm-50nm; or / and The chitosan is chitosan specially used for medical purposes.

3. The wound healing agent according to claim 2, characterized in that: In the plant extract, the mass ratio of the tea polyphenols to the aloe extract is 1:(1-1.2); or / and Among the auxiliary components, the mass ratio of the solubilizer, the stabilizer, the moisturizer, and the antioxidant is 1:(0.02-0.5):(0.01-0.2):(0.01-0.1).

4. The wound healing agent according to any one of claims 1 to 3, characterized in that: The pH of the wound healing agent is less than 2.7; or / and The redox potential value of the wound healing agent is greater than 1100 MV.

5. A method for preparing the wound healing agent according to any one of claims 1 to 4, characterized in that: include: S100, preparing a chitosan solution: adding chitosan and a solubilizing agent into medical purified water, and stirring until the chitosan is completely dissolved to obtain the chitosan solution; S200, preparing a hypochlorous acid solution: preparing a sodium chloride solution, and electrolyzing the sodium chloride solution to obtain the hypochlorous acid solution; S300, preparing a wound healing agent: slowly adding the hypochlorous acid solution to the chitosan solution, adding a stabilizer to adjust the pH, stirring evenly, and adding colloidal silver particles, plant extracts, moisturizers, and antioxidants during stirring to obtain the wound healing agent; Wherein, the concentration of the chitosan solution is 5g / L-20g / L; The concentration of the sodium chloride solution is 10g / L-20g / L; The plant extracts include tea polyphenols and aloe extracts.

6. The preparation method according to claim 5, characterized in that: The preparation method of the colloidal silver particles comprises: S301, dissolving silver nitrate in medical purified water and stirring, and slowly dropping a reducing agent solution and a silver ion stabilizer during the stirring process until the solution turns light yellow or brown; S302, cooling the solution in S301 and then centrifuging it to obtain the colloidal silver particles; Wherein, the concentration of the silver nitrate solution is 0.01mol / L-0.1mol / L; The concentration of the reducing agent solution is 0.1 mol / L-0.2 mol / L.

7. The preparation method according to claim 6, characterized in that: In the S301, The stirring treatment is carried out in a light-shielded place or a dark place; or / and The stirring temperature is 60°C-80°C; or / and The stirring time is 10 min to 30 min; or / and The reducing agent solution is a sodium citrate solution or an ascorbic acid solution; or / and The silver ion stabilizer is sodium citrate or polyvinyl pyrrolidone.

8. The preparation method according to claim 5, characterized in that: In S300, the pH is adjusted to less than 2.7; or / and The S300 is performed under ultrasonic conditions.

9. The preparation method according to claim 5, characterized in that: In the S200, The voltage of the electrolysis treatment is 4V-6V; or / and The electrolysis treatment time is 10min-30min; or / and The temperature of the electrolysis treatment is 20°C-30°C.

10. The preparation method according to claim 5, characterized in that: The solubilizing agent includes any one of acetic acid, lactic acid, carboxymethyl cellulose, phospholipids, and polysorbate; or / and The stabilizer includes: any one of citric acid, sodium citrate, lactic acid, and sodium lactate; or / and The moisturizing agent includes any one of glycerin, hyaluronic acid, propylene glycol, polyvinyl alcohol, and ceramide; or / and The antioxidant comprises any one of vitamin E, glutathione, ascorbic acid, BHT, rosemary extract, and beta-carotene extract.

Images